Nassib Jowan, Hireche Kheira, Ozdemir Baris Ata, Alric Pierre, Canaud Ludovic
Department of Thoracic and Vascular Surgery, Arnaud de Villeneuve Hospital, Montpellier, France.
PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.
J Endovasc Ther. 2022 Oct;29(5):773-779. doi: 10.1177/15266028211065964. Epub 2021 Dec 27.
This study assessed morphological changes in the aortic true and false lumens during follow-up of patients undergoing TEVAR (Thoracic Endovascular Aortic Repair) for complicated acute and subacute type B dissection. The study analyzes the effectiveness of TEVAR in preventing distal aneurysmal progression.
All patients between 2009 and 2019 undergoing TEVAR for complicated acute and subacute type B dissection at the study institution were retrospectively reviewed. Maximal diameters were measured on the proximal descending aorta right below the left subclavian artery, thoraco-abdominal junction right above the celiac trunk, and infrarenal aortic right above the inferior mesenteric artery, pre-operatively and during follow-up, analyzing either expansion or shrinkage of true and false lumens at these 3 sites.
Forty-one patients were included. Thirty-day incidence of death, stroke, paraplegia, and visceral ischemia was, respectively, 8% (n = 4), 6% (n = 3), 2% (n = 1), and 2% (n = 1). Three patients (6%) died from intervention-related cause. Mortality was 17% (n = 8) during a mean follow-up of 54 months. One patient had aneurysmal dilation of the descending aorta needing additional coverage and only 2 (4%) developed thoraco-abdominal aneurysms requiring re-intervention. In the remaining patients, both significant expansion of the true lumen and shrinkage of false lumen were observed at all 3 sites.
Proximal coverage of the main entry tear appears to prevent aneurysmal progression in most patients (96%). With such promising results, TEVAR should be considered as a first-line treatment in acute and subacute type B dissection.
本研究评估了接受胸主动脉腔内修复术(TEVAR)治疗复杂急性和亚急性B型主动脉夹层患者随访期间主动脉真腔和假腔的形态学变化。该研究分析了TEVAR在预防远端动脉瘤进展方面的有效性。
对2009年至2019年期间在本研究机构接受TEVAR治疗复杂急性和亚急性B型主动脉夹层的所有患者进行回顾性分析。在术前和随访期间,测量左锁骨下动脉下方的近端降主动脉、腹腔干上方的胸腹交界处以及肠系膜下动脉上方的肾下腹主动脉的最大直径,分析这3个部位真腔和假腔的扩张或缩小情况。
纳入41例患者。30天内死亡、卒中、截瘫和内脏缺血的发生率分别为8%(n = 4)、6%(n = 3)、2%(n = 1)和2%(n = 1)。3例患者(6%)死于与干预相关的原因。平均随访54个月期间的死亡率为17%(n = 8)。1例患者降主动脉出现动脉瘤样扩张,需要额外覆盖,仅2例(4%)发生胸腹主动脉瘤,需要再次干预。在其余患者中,所有3个部位均观察到真腔显著扩张和假腔缩小。
封堵主要入口撕裂的近端似乎可防止大多数患者(96%)的动脉瘤进展。鉴于如此有前景的结果,TEVAR应被视为急性和亚急性B型主动脉夹层的一线治疗方法。